Vision
Why We Exist
The Addiction Paradox: Modern Vaping, Outdated Tools
Despite technological advances in nicotine delivery, most cessation tools remain relics of the 1980s. As sleek devices and flavored cartridges flood the market, young users are left with static, impersonal patches and gums that fail to adapt to their behavioral patterns or neuropsychological profiles.
The Surge in Use
- Between 2017 and 2019, past-month nicotine vaping doubled among high school students:
- 12th graders: 11% → 25%
- 10th graders: 8% → 20%
- 8th graders: 4% → 9%
- College vaping spiked from 6% to 16% within a single year.
- 31% of students cite flavors as a reason for use; 39% cite peer and family influence.
Misaligned Perceptions
- Only 22% of adults under 30 believe vaping is very harmful, despite mounting evidence linking it to EVALI and chronic lung damage.
- Conventional NRTs fail to accommodate individualized behavioral cues, cravings, or engage users with real-time feedback.
Broken Feedback Loops
- Most users must guess how to taper, lacking physiological monitoring or adaptive support.
- No system integrates what users feel, what they do, and what they truly need next.
Meanwhile, a substantial shift from combustible tobacco products to e-cigarettes has emerged. Although vaping reduces carcinogen exposure relative to traditional smoking, it introduces new public health challenges—particularly among adolescents. Despite fluctuations, 10% of high schoolers and 4.6% of middle schoolers currently vape, with nearly half expressing a desire to quit.
Vaping is not benign: nicotine inhalation through e-cigarettes has been linked to cardiovascular and pulmonary dysfunction, fetal development complications, and increased health risks. Although nicotine tapering strategies show promise in tobacco cessation, vaping-specific research remains sparse. Studies reveal compensatory puffing behaviors—users inhale more deeply or frequently with lower nicotine concentrations—increasing exposure to harmful substances.
Between 2017 and 2022, average nicotine concentrations in disposable e-cigarettes surged 294%, exacerbating dependence risks. While flavors can enhance cessation success for cigarette smokers, they also significantly heighten vaping’s abuse potential among youth.
These realities underscore the urgent need for smarter, tailored interventions that directly address the unique dynamics of vaping behavior—gaps that existing methods have failed to bridge.
Our Vision: Intelligent, Adaptive Treatment
At Recalivape, we believe the future of addiction care must be:
- Personalized by data,
- Adaptive to behavior,
- Accountable to society.
Nicotine dependence is not merely a chemical imbalance—it is a feedback loop shaped by neurobiology, behavioral conditioning, and environmental design. Yet most cessation tools reduce the complexity of addiction to static, impersonal solutions.
We envision a different path: a future where smart devices, machine learning, and behavioral science work in harmony to create real-time, personalized support systems. A future where quitting does not mean facing the journey alone, and relapse becomes less likely—not more inevitable.
We fundamentally reject outdated, generic solutions. Our intelligent, adaptive framework integrates real-time physiological monitoring, behavioral feedback, and personalized interventions to transform addiction treatment:
Sensory Monitoring & Adaptive Response (SMART) Module
A modular, sensor-integrated attachment compatible with existing vaping devices. It precisely captures puff frequency, duration, intensity, and physiological metrics, converting everyday devices into real-time behavioral research tools.
Adaptive Modular Substance Treatment Analysis Device (AMSTAD)
Our long-term vision is a fully autonomous, closed-loop cessation platform. AMSTAD integrates live sensor data with machine learning algorithms to dynamically adjust nicotine dosing based on each individual’s physiological and behavioral needs.
Expansion to Multi-Substance Management
Our modular platform is inherently scalable, enabling future treatment adaptations for THC, opioids, cannabis, and other aerosolized therapeutics, thereby expanding our clinical impact.
We follow a structured innovation pathway: SMART Module Deployment → AMSTAD Integration → Expansion Across Substances—building an evidence-based, adaptable, and clinically robust architecture for substance use treatment.
Our Guiding Pillars
Science-Informed
Our products are developed through rigorous research, IRB-approved studies, and clinical collaboration—with a steadfast commitment to data integrity and scientific transparency.
Technologically Empowered
We deploy sensors, AI, and modular IoT technologies to create platforms that not only track addiction but actively transform it through intelligent feedback.
Human-Centered
Our focus is not on devices—it is on people. We engineer interventions rooted in lived experience, guided by empathy, personalization, and accessibility.
Scalable for Impact
We are not merely building a product; we are constructing an adaptable ecosystem capable of addressing diverse substances, populations, and global health challenges.
Through this vision, Recalivape seeks to redefine addiction treatment: empowering recovery through personalization and setting a new global standard for smart, data-driven, and adaptive therapeutic technology.